Sulindac should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.Sulindac has not been established as safe for use in pregnant or lactating women.Congenital abnormalities have been reported in association with NSAID administration in man; however, these are low in frequency and do not appear to follow any discernible pattern. 101 terms. About 50% is excreted in the urine mainly as a sulphone metabolite and its glucuronide conjugate. Back to top. 10mm flat bevel-edged orange yellow tablet marked “SD” breakline “200” on one side and “α” on the … … Log in Sign up. NSAIDs should not be used during the first two trimesters of pregnancy or labour unless the potential benefit to the patient outweighs the potential risk to the foetus.In limited studies so far available, NSAIDs can appear in breast milk in very low concentrations. 4.5 Interaction with other medicinal products and other forms of interaction6.6 Special precautions for disposal and other handling9. POM: Prescription only medicine. Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment.
In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of sulindac should be considered.Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. sulindac; Legal Category. This site uses cookies. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and section 4.5).Patients with a history of GI toxicity, particularly older people, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.Caution should be advised in patients receiving concomitant medications which could increase the risk of gastrotoxicity or bleeding, such as corticosteroids, or anticoagulants such as warfarin or anti-platelet agents such as aspirin (see section 4.5).When GI bleeding or ulceration occurs in patients receiving sulindac, the treatment should be withdrawn.NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8).In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis (see section 4.8).Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Excipients with known effect: Each tablet contains 36 mg of lactose monohydrate. Report Side Effect; Related Medicines. The patient should be monitored regularly for GI bleeding during NSAID therapy.Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.NSAIDS are contraindicated in patients who have previously shown hypersensitivity reactions (e.g. Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke)Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with sulindac after careful consideration.
Ces cookies permettent d’interagir depuis le site Le Vidal avec les modules sociaux et de partager les contenus du site du avec d’autres personnes, lorsque vous cliquez sur le module "Partager", de Facebook et de Twitter, par exemple. Pharmaceutical form. Nos équipes font le maximum pour résoudre ce problème rapidement. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. Children—Use and dose must be determined by your doctor. It is metabolised by reversible reduction to the sulphide metabolite, which appears to be the biologically active form, and by irreversible oxidation to the sulphone metabolite. Alternatively, in adults, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose.Renal and liver function should be closely monitored.Patients should be observed for at least four hours after ingestion of potentially toxic amounts.Frequent or prolonged convulsions should be treated with intravenous diazepam.Other measures may be indicated by the patient's clinical condition.Sulindac is a fluorinated indene with a structural resemblance to indometacin.